Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Liminal BioSciences Inc. (T:LMNL)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LMNL within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jul 22, 2020 07:55 ET
Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
LAVAL, QC and CAMBRIDGE, England, July 22, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announces that it has applied for a voluntarily delisting of its common shares ("Common Shares") from the Toronto Stock Exchange ("TSX") in Canada. Subject to such application being accepted by the TSX, it is expected that the Common Shares will be delisted from the TSX effective as of the close of trading on August 5, 2020.
Read full article
Jul 22, 2020 07:55 ET
Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
LAVAL, QC and CAMBRIDGE, England, July 22, 2020 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announces that it has applied for a voluntarily delisting of its common shares ("Common Shares") from the Toronto Stock Exchange ("TSX") in Canada. Subject to such application being accepted by the TSX, it is expected that the Common Shares will be delisted from the TSX effective as of the close of trading on August 5, 2020. ...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.82
--
--
Price to Sales - TTM
65.12
15.50
12.51
Price to Book - most recent quarter
4.85
5.36
4.00
Price to Cash Flow per share - TTM
--
5.72
16.26
Price to Free Cash Flow per share - TTM
--
31.85
27.60
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jul 31, 2020136,292120,477
Dec 31, 196900
Dec 31, 196900
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Liminal BioSciences Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing treatments for patients suffering from diseases primarily related to fibrosis, including respiratory, liver and kidney diseases. The Company operates through two segments: Small Molecule Therapeutics Segment and Plasma-derived Therapeutics Segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. Its lead small molecule product candidate is fezagepras (PBI-4050). The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Its lead plasma-derived product candidate is Ryplazim (plasminogen).

See business summary

 

Twitter

Search (past week) for $LMNL.CA

  • No tweets found